Month: August 2023

Triples Transform and Grow Plan to $300 Million Provides Updated Full Year 2023 Outlook RICHARDSON, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the fiscal second quarter ended July 1, 2023. Second Quarter SummarySecond quarter worldwide net sales totaled $322 million, decreasing 13%.Net sales in the Company’s direct to consumer channels were down 4% in constant currency, with comparable retail sales growth of 3%. Net sales in our wholesale channels were down 19%.FOSSIL brand sales grew slightly in traditional watches, more than offset by declines in smartwatches and leathers, resulting in a total brand sales decline of 8% in constant currency.Operating loss of $35 million compared to a loss of $11 million a year ago. Adjusted operating loss of $28 million...

– Second Quarter Revenues and Share of NPI Revenues Interest total $62.0 million, up 98.2% year-over-year – – Expected Timeline for Completion of the Aristocrat Business Combination Remains the First Half of 2024 – LUXEMBOURG, Aug. 09, 2023 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery and iGaming solutions, announced today financial results for the second quarter ended June 30, 2023. Moti Malul, Chief Executive Officer of NeoGames, said: “We are very pleased with the achievements and partnerships that defined and drove our second quarter results. Our continued commitment to innovation and excellence has paved the way for expansion across various global markets, with progress during the second quarter of 2023 across all of our business...

Provides Update to Full Year 2023 Financial Guidance PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights:Revenue was $90.5 million, compared to $82.8 million in the second quarter of 2022, representing growth of 9% over the second quarter of 2022 on a reported basis and 10% at constant currency. Net income was $4.7 million, compared to a net loss of $0.6 million in the second quarter of 2022. Adjusted EBITDA was $32.4 million, compared to $28.0 million in the second quarter of 2022.“During the second quarter our software business performed well, but we experienced lower growth than expected in our services business due to cautious spending among smaller biotech...

LAFAYETTE, La., Aug. 09, 2023 (GLOBE NEWSWIRE) — Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and six months ended June 30, 2023. Operational highlights (all dollar amounts are USD):Net revenues attributable to the Company’s core business for the quarter ended June 30, 2023 reached a new Company record of $43.3 million, representing an increase of $10.2 million, or 31%, over core net revenues reported for the comparable quarter ended June 30, 2022. Net revenues for the quarter ended June 30, 2023 included approximately $2.5 million of revenues related to the HMP acquisition and were up approximately 9% over the quarter ended...

Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022;Year-to-Date Revenue Increases 45%; Maintains Positive Cash Flow Results SOUTH ORANGE, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2023. Financial Highlights*Net revenue from continuing operations of $3.5 million, an increase of 24% Net loss from continuing operations of $0.4 million, compared to $0.7 million Adjusted EBITDA from continuing operations of ($0.2 million), compared to ($0.4 million)*Stated performance is relative to same period prior year (second quarter of 2022) “Last quarter, Nephros achieved two significant milestones: positive...

Second Quarter Financial Highlights: (comparisons are year over year)Total revenues increased 15.2% year over year to $468.4 million Construction and Material Handling revenues of $281.5 million and $169.1 million, respectively Newly introduced reporting segment, Master Distribution, with revenues of $21.4 million Product Support revenues increased 19.1% year over year with Parts Sales increasing to $71.3 million and Service Revenues increasing to $59.7 million New and Used Equipment sales grew 17.2% to $254.6 million Net income of $1.7 million available to common stockholders compared to $5.4 million in 2022 Basic and diluted net income per share of $0.05 for 2023 compared to $0.17 in 2022 Adjusted basic and diluted net income per share* of $0.19 for 2023 compared to $0.26 for 2022 Adjusted EBITDA* grew 20.5% to $49.9 million, compared...

TARRYTOWN, NY, Aug. 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023. Recent HighlightsAnnounced positive top line results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301, paving the way for an expected NDA filing in 2024 Granted Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with autism spectrum disorder (“ASD”) and their families Submitted PAX-101...

PITTSBURGH, Aug. 09, 2023 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the second quarter ended June 30, 2023. Second Quarter Financial Highlights:Revenues of $53.3 million, decreased 21.5% as compared to the second quarter of 2022 Net Income of $1.0 million, decreased 94.8% as compared to the second quarter of 2022 Non-GAAP Adjusted EBITDA of $19.2 million, decreased 30.4% as compared to the second quarter of 2022 RNG production of 1.4 million MMBtu, decreased 2.6% as compared to the second quarter of 2022On June 21, 2023, the Environmental Protection Agency announced final rules for the Renewable Fuel Standard for...

First Half Record Net Revenue Focus is to Reduce Cost Structure and Transform Operations LAS VEGAS, Aug. 09, 2023 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG), a leading food distributor to Asian restaurants across the United States (“HF Foods”, “HF Group” or the “Company”), reported financial results for the second quarter and six months ended June 30, 2023. Second Quarter 2023 Financial ResultsNet revenue decreased 2.4% to $292.3 million compared to $299.6 million in the prior year. Gross profit decreased 3.6% to $50.7 million, or 17.3% gross profit margin compared to $52.6 million, or 17.5% gross profit margin in the prior year. Net (loss) income decreased to a net loss of $1.6 million compared to net income of $4.5 million in the prior year. Adjusted EBITDA decreased 50.1% to $6.9 million compared to $13.9 million...

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights. “During the second quarter of this year, Context continued development of our preclinical asset CTIM-76, a Claudin 6 (“CLDN6”) x CD3 bispecific antibody. An immunotherapy designed to activate and direct a patient’s own immune cells, CTIM-76 shows a high degree of specificity in preclinical studies and the potential...